Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab

Annunziata Dattola; Martina Tolone; Emanuele Amore; Luigi Bennardo; Simone Amato; Teresa Grieco; Antonio Giovanni Richetta; Giovanni Pellacani; Nevena Skroza; Steven Paul Nisticò

doi:10.5826/dpc.1403a204

Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab

Authors

Annunziata Dattola Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Martina Tolone Department of Health Sciences- Unit of Dermatology, Magna Graecia University, Catanzaro, Italy
Emanuele Amore Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Luigi Bennardo Department of Health Sciences- Unit of Dermatology, Magna Graecia University, Catanzaro, Italy
Simone Amato Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Teresa Grieco Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Antonio Giovanni Richetta Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Giovanni Pellacani Department of Dermatology University of Rome “La Sapienza”, Rome, Italy
Nevena Skroza Dermatology Unit ‘Daniele Innocenzi’, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina, Italy
Steven Paul Nisticò Department of Dermatology University of Rome “La Sapienza”, Rome; Department of Health Sciences- Unit of Dermatology, Magna Graecia University, Catanzaro, Italy

Keywords:

atopic dermatitis, anti IL13, tralokinumab, biologic therapy

Abstract

Introduction: The advent of biotechnological drugs has significantly changed the management of atopic dermatitis (AD) and the approach to the moderate-to-severe form of this chronic relapsing disease.

Objectives: The aim of our review is to summarize the current literature on anti-interleukin (IL)-13 in atopic dermatitis.

Methods: A literature search was organized and a systematic review was performed to summarize the most recent evidence supporting the efficacy and safety of tralokinumab.

Results: Tralokinumab (anti-IL-13) 300 mg every 2 weeks subcutaneously has proven effective in several clinical trials in adults and adolescents with moderate to severe atopic dermatitis inadequately controlled with other topical or systemic therapies. Tralokinumab was found to be significantly superior in terms of efficacy in reducing IGA, EASI-75, NRS pruritus, and DLQI scale numbers. During follow-up, tralokinumab was well tolerated with limited severity of adverse events.

Conclusion: Tralokinumab leads to statistically significant improvements in disease severity and outcome scores. It represents an effective treatment option for adults with moderate to severe AD, but further large-scale studies are needed to verify long-term superiority over other treatments.

References

Gargiulo L, Ibba L, Vignoli CA, et al. Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. J Dermatolog Treat. 2023 Dec;34(1):2216815. doi: 10.1080/09546634.2023.2216815. PMID: 37246920.

Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118–27.

Tanei R. Atopic dermatitis in the elderly. Inflamm Allergy Drug Targets. 2009;8:398–404.

Nettis E, Ortoncelli M, Pellacani G, et al. A multicenter study on the prevalence of clinical patterns and clinical phenotypes in adult atopic dermatitis. J Investig Allergol Clin Immunol. 2020;30(6):448-450.

Morelli P, Gaspari M, Gabriele C et al. Proteomic analysis from skin swabs reveals a new set of proteins identifying skin impairment in atopic dermatitis. Exp Dermatol. 2021 Jun;30(6):811-819.

Bonnart C, Deraison C, Lacroix M, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest. 2010;120:871–82

Dattola A, Bennardo L, Silvestri M, Nisticò SP. What's new in the treatment of atopic dermatitis? Dermatol Ther. 2019 Mar;32(2):e12787.

May RD, Monk PD, Cohen ES, et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 166 (2012) 177–193.

Silverberg JI, Kantor R. The role of interleukins 4 and/or 13 in the pathophysiology and treatment of atopic dermatitis. Dermatol Clin. 2017 Jul;35(3):327-334. doi: 10.1016/j.det.2017.02.005. Epub 2017 Apr 22. PMID: 28577802.

Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994;94(2):870–876.

Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice re- sults in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol. 2001;117(4):977–983.

Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2011;2(3):110.

Tazawa T, Sugiura H, Sugiura Y, et al. Relative impor- tance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459–64.

Hamid Q, Naseer T, Minshall EM, et al. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996;98(1):225–31.

Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129(3):742–51.

Hijnen D, Knol EF, Gent YY, et al. CD8(1) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013;133(4):973–9.

Burd PR, Thompson WC, Max EE, et al. Activated mast cells produce interleukin 13. J Exp Med. 1995;181(4):1373–80.

Li H, Sim TC, Alam R. IL-13 released by and localized in human basophils. J Immunol .1996;156(12): 4833–4838.

Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002; 169(2):1021–7.

Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;186(12):7232–7242.

Howell MD, Kim BE, Gao P, et al. Cytokine modula- tion of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150–5.

Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008; 126(3):332–337.

Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017; 171:217-228.e213.

Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020 Jan;75(1):54-62. doi: 10.1111/all.13954. Epub 2019 Jul 15. PMID: 31230370.

Tollenaere MAX, Mølck C, Henderson I, Pollack S, Addis P, Petersen HH, Norsgaard H. Tralokinumab effectively disrupts the IL-13/IL-13Rα1/IL-4Rα signaling complex but not the IL-13/IL-13Rα2 complex. JID Innov. 2023 Jul 4;3(5):100214. doi: 10.1016/j.xjidi.2023.100214. PMID: 37554517; PMCID: PMC10405097.

Li Y, Li H, Yang F, Smith-Gill S, Mariuzza RA. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat Struct Mol Biol. 2003;10:482–488.

Fransson F, Teplyakov A, Raghunathan G, et al. Human framework adaptation of a mouse anti-human IL-13 antibody. J Mol Biol. 2010;398: 214–231.

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437-449.

Torres T, Sohrt Petersen A, Ivens U, Bosch Vilaro A, Stinson J, Carrascosa JM. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). doi:10.1007/s13555-024-01143-x

Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. doi:10.1111/all.16108

Simpson EL, Blauvelt A, Silverberg JI, et al. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1. Am J Clin Dermatol. 2024;25(1):139-148. doi:10.1007/s40257-023-00817-0

Cozzani E, Marzano AV, Caproni M, Feliciani C, Calzavara-Pinton P. Cutaneous Immunology group of SIDeMaST. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. G Ital Dermatol Venereol. 2018 Jun;153(3):305-315. doi: 10.23736/S0392-0488.18.06006-6. Epub 2018 Mar 30. PMID: 29600832.

Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020; https://doi. org/10.1111/bjd.19573.

Silverberg JI, Adam DN, Zirwas M, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: An ECZTRA 3 post hoc analysis. Am J Clin Dermatol. 2022 Jul;23(4):547-559. doi: 10.1007/s40257-022-00702-2. Epub 2022 Jul 20. PMID: 35857179; PMCID: PMC9334431.

Alegre-Bailo A, Sánchez-Gilo A, Marlene-Mendoza NM, Mateos-Rico JJ, Vicente-Martín FJ. Tralokinumab treatment in atopic dermatitis: Depicting super-responders. J Dermatol. 2023 Oct 23. doi: 10.1111/1346-8138.17009. Epub ahead of print. PMID: 37870261.

Gutermuth J, Pink AE, Worm M, Soldbro L, Bjerregård Øland C, Weidinger S. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022 Mar;186(3):440-452. doi: 10.1111/bjd.20832. Epub 2021 Dec 22. PMID: 34698371.

Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019 Jan;143(1):135-141. doi: 10.1016/j.jaci.2018.05.029.

Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19. PMID: 35863467.

Ewulu AR, Prajapati S, Feldman SR. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents. Immunotherapy. 2023 Nov;15(16):1341-1349. doi: 10.2217/imt-2022-0307. Epub 2023 Aug 29. PMID: 37641871.

Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: The Phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023 Jun 1;159(6):596-605. doi: 10.1001/jamadermatol.2023.0627. Erratum in: JAMA Dermatol. 2023 Jun 1;159(6):673. PMID: 37074705; PMCID: PMC10116386.

Merola JF, Butler DC, Mark T, Schneider S, Kim Y, Abuabara K. Safety and efficacy of tralokinumab in older adults with moderate-to-severe atopic dermatitis: a secondary analysis. JAMA Dermatol. 2023 Oct 1;159(10):1119-1123. doi: 10.1001/jamadermatol.2023.2626. PMID: 37610789; PMCID: PMC10448370.